By Chris Villani (April 2, 2018, 2:34 PM EDT) -- A Massachusetts federal judge on Friday tossed a proposed class action against a venture capital-backed Bay State biotech company, saying its optimistic outlook about a pill-based colon infection treatment did not amount to securities fraud when an unsuccessful trial of the drug caused the company's stock to plummet.
U.S. District Judge Denise J. Casper granted the motion to dismiss by Seres Therapeutics Inc., a Cambridge, Massachusetts, startup biopharmaceutical company that had designed a drug meant to treat a recurring colon infection. The suit, brought by the asset management group Erste-Sparinvest Kapitalanlagegesellschaft mbH and the Oklahoma Law Enforcement Retirement System, claimed Seres...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!